EQT Fund Management’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$57.1M Hold
5,141,992
– – 6.02% 4
2026
Q2
$66.7M Hold
5,141,992
– – 7.74% 5
2026
Q1
$53.9M Buy
+5,141,992
New +$72.8M 5.28% 5

Other funds holding AGMB

EQT Fund Management's AGMB Position: Q3 2026 in Review

EQT Fund Management held its AgomAb Therapeutics NV (AGMB) position steady in Q3 2026 at 5,141,992 shares worth $57.1M. The position accounts for 6.02% of the portfolio, ranked #4.

EQT Fund Management first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $66.7M in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • EQT Fund Management held 5,141,992 shares of AgomAb Therapeutics NV worth $57.1M as of Q3 2026.
  • EQT Fund Management left its AgomAb Therapeutics NV share count unchanged in Q3 2026.
  • AgomAb Therapeutics NV made up 6.02% of EQT Fund Management's portfolio in Q3 2026, its #4 holding.
  • EQT Fund Management first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • EQT Fund Management's AgomAb Therapeutics NV position peaked at $66.7M in Q2 2026.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on EQT Fund Management's 13F filing for Q3 2026, filed 12 Nov 2026.